Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 1063 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

1,063 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 1,063 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,063 programs

Clinical programs

Page 1 of 23

  1. 10-week smoking cessation group therapy combined with NicoDerm CQ

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Cessation

    phase 3 other completed

    1 trial

  2. 811095

    BRIGHT MINDS BIOSCIENCES INC.

    Amphetamine Dependence

    phase 3 small molecule completed

    1 trial

  3. Active referral

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 3 other active

    1 trial

  4. Acyclovir

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  5. Adderall-XR

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 3 small molecule completed

    1 trial

  6. Agitated Saline SoC

    BRIGHT MINDS BIOSCIENCES INC.

    Right-To-Left Shunt

    phase 3 small molecule active

    1 trial

  7. B007

    BRIGHT MINDS BIOSCIENCES INC.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    2 trials

  8. B007

    BRIGHT MINDS BIOSCIENCES INC.

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  9. B013+Nab-Paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Triple Negative Breast Cancer (TNBC)

    phase 3 small molecule completed

    1 trial

  10. Bedaquiline

    BRIGHT MINDS BIOSCIENCES INC.

    Multi-drug Resistant Tuberculosis

    phase 3 small molecule active

    1 trial

  11. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    HCV Negative Status

    phase 3 other completed

    1 trial

  12. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Behavior Therapy

    phase 3 other completed

    1 trial

  13. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 3 other completed

    3 trials

  14. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 3 other completed

    1 trial

  15. Behavioral Drug and HIV Risk Reduction Counseling

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Dependence

    phase 3 other completed

    1 trial

  16. Bias retraining

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Use Disorder

    phase 3 other completed

    1 trial

  17. Booster Sessions

    BRIGHT MINDS BIOSCIENCES INC.

    Skill Development of Staff

    phase 3 other completed

    1 trial

  18. Brief Strategic Family Therapy (BSFT)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 other completed

    1 trial

  19. Brief advice

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    phase 3 other completed

    1 trial

  20. Brief motivational intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Use

    phase 3 other completed

    1 trial

  21. Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 3 small molecule completed

    5 trials

  22. Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 3 small molecule completed

    2 trials

  23. Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 3 small molecule active

    1 trial

  24. Buprenorphine + Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 3 small molecule completed

    1 trial

  25. Buprenorphine +OTP

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Addiction

    phase 3 small molecule completed

    1 trial

  26. Buprenorphine Injection

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 3 small molecule completed

    1 trial

  27. Buprenorphine/Naloxone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule terminated

    1 trial

  28. Buprenorphine/naloxone

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 3 small molecule completed

    2 trials

  29. Buprenorphine/naloxone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 3 small molecule terminated

    6 trials

  30. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 3 small molecule completed

    1 trial

  31. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 3 small molecule active

    3 trials

  32. CI-581a

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 3 small molecule on hold

    1 trial

  33. Cannabidiol

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder (OUD)

    phase 3 small molecule active

    1 trial

  34. Capsaicin

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetic Polyneuropathy

    phase 3 small molecule completed

    1 trial

  35. Cetirizine

    BRIGHT MINDS BIOSCIENCES INC.

    COVID-19

    phase 3 small molecule terminated

    1 trial

  36. Chestnut Bloomington Outpatient (CBOP)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 other completed

    1 trial

  37. Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Squamous Cell Carcinoma of Head and Neck

    phase 3 small molecule active

    1 trial

  38. Clonidine HCL

    BRIGHT MINDS BIOSCIENCES INC.

    Neonatal Abstinence Syndrome

    phase 3 small molecule completed

    2 trials

  39. Cognitive Behavioral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 other completed

    1 trial

  40. Cognitive Behavioral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Stress Disorders, Post-Traumatic

    phase 3 other completed

    1 trial

  41. Counseling + Transfer

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Addiction

    phase 3 small molecule completed

    1 trial

  42. Deferiprone oral solution

    BRIGHT MINDS BIOSCIENCES INC.

    Pantothenate Kinase-Associated Neurodegeneration

    phase 3 small molecule completed

    1 trial

  43. Depot naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Addiction

    phase 3 small molecule completed

    1 trial

  44. Descovy or Truvada

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  45. Directly administered antiretroviral therapy (DAART)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 other completed

    2 trials

  46. Divalproex Sodium

    BRIGHT MINDS BIOSCIENCES INC.

    Attention Deficit and Disruptive Behavior Disorders

    phase 3 small molecule completed

    1 trial

  47. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    1 trial

  48. Dronabinol Capsules

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

1,063 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.